tbuckley/cabot-search huggingface dataset:
Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC) and genotype UGT1A1*1/ UGT1A1*1 or UGT1A1*1/ UGT1A1*28 (FFCD 0504 trial). Results of a planned interim analysis
Authors: E. Mitry, O. Bouché, L. Dahan, F. Bonnetain, P. Laurent-Puig, T. Aparicio, P. L. Etienne, C. Lecaille, J. P. Lafargue, J. L. Jouve
Journal: Journal of Clinical Oncology (2009)

4065 Background: The antitumor efficacy of irinotecan may be dose dependent. In a recent phase II trial, the combination of high-dose irinotecan (260 mg/m 2 ) with LV5FU2 regimen was feasible with an acceptable safety profile and promising efficacy data (Ducreux et al. Oncology 2008;74:17–24). The aim of this study was to evaluate the association of the high-dose FOLFIRI plus bevacizumab in patients (pts) selected on the UGT1A1 polymorphism, which could be predictive of the irinotecan toxicity. Methods: Pts with UGT1A1 *1/*1 (group 1) or *1/*28 (group 2) genotypes and previously untreated mCRC were treated with bevacizumab 5 mg/kg D1, irinotecan 260 mg/m 2 D1, LV 400 mg/m 2 D1, 5FU 400 mg/m 2 IV bolus D1 and 5FU 2400 mg/m 2 46h infusion D1–2 every 2 weeks. Using Bryant &amp; Day design with OR (independent review, H0 ≤ 40%; H1 : ≥ 60%) and toxicity (gr 4 neutropenia or febrile neutropenia or gr3–4 diarrhea; H0 ≥ 20%; H1≤ 5% ) as primary endpoints; a total of 108 pts, 54 in each group, was required (alpha 5% and power 80%) with a planned interim analysis after the inclusion of 17 pts by group. The trial will be stopped at interim analysis if ≤ 7 pts had an OR and/or ≥ 3 pts had a severe toxicity. All analyses were performed in ITT. Results: At the time of interim analysis, done for group 1 when the 17th pt had a 6-months follow-up, 96 pts have been included (group 1: 40 pts, group 2: 46 pts). An objective response rate was observed in 9/17 pts but 7/17 pts had a severe toxicity (gr 4 neutropenia: 2 pts, febrile neutropenia: 2 pts, gr 3 diarrhea: 4 pts). Overall, 14/17 pts had a gr3–4 toxicity. There was no toxic death. According to interim analysis rules, the trial was closed to inclusion (for both groups) on December 16th 2008 for toxicity. The interim analysis for pts of group 2 is planned for February 2009 when the 17th patient will have a 6-months follow- up. Conclusions: High-dose FOLFIRI plus bevacizumab, although effective, was associated with a high toxicity rate among pts with UGT1A1 *1/*1 genotype. Complete tolerance, efficacy and survival results for all included patients will be presented at the meeting. [Table: see text]
PLATELETS AND VON WILLEBRAND FACTOR INTERACTIONS AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR): ASSOCIATION WITH THROMBOCYTOPENIA AND THROMBOSIS
Authors: Homam Ibrahim, Timothy DeLao, Leticia Nolasco, Colin Barker, Joel Moake, Michael Reardon, Neal Kleiman
Journal: Journal of the American College of Cardiology (2017)
USE OF PHARMACOMECHANICAL THROMBECTOMY IN A PATIENT WITH ACUTE PULMONARY EMBOLISM AND IMMINENT HEMODYNAMIC COLLAPSE AT VERY HIGH RISK FOR CEREBRAL HEMORRHAGE
Authors: Geurys Rojas-Marte, Menhel Kinno, Monali Patel, Adebayo Olusanya, Pallavi Solanki
Journal: Journal of the American College of Cardiology (2017)
Abstract 75: Ischemic Heart Failure is Exacerbated in CD39-null Mice
Authors: Tatiana Novitskaya, Debra G Wheeler, Zhaobin Xu, Elena Chepurko, Bo Zhang, Walter Koch, Karen M Dwyer, Peter J Cowan, Simon C Robson, Erhe Gao, Richard J Gumina
Journal: Circulation Research (2015)

Background: CD39 (ectonucleoside triphosphate diphosphohydrolase) is a nucleotidase expressed on endothelial cells, vascular smooth muscles cells, and leukocytes. CD39 plays a key role in vascular homeostasis, hydrolyzing extracellular ATP and ADP. CD39 has been shown to be important in models of ischemic preconditioning and cardiac ischemia reperfusion. However, the effect of CD39 activity on functional recovery of heart after myocardial infarction (MI) has not been evaluated. Hypothesis: Genetic ablation of CD39 expression exacerbates post-myocardial infarction cardiac function and fibrosis. Methods: Wild-type (WT) and CD39-null mice were subjected to coronary artery ligation. Cardiac function and protein evaluation of fibrotic markers was performed at day 28 post-MI. Results: Evaluation at Day 28 post-MI revealed that while mice of both genotypes had similarly reduced ejection fraction and equally compromised contractile function (dP/dtmax), there was a more pronounced negative effect on lusitropy (dP/dtmin) and increased left ventricular end-diastolic pressure in CD39-null mice. Therefore, cd39 gene ablation associates with the development of worsening cardiac performance. Histological analysis revealed increased collagen deposition and abundance of alpha-smooth muscle actin (αSMA) positive interstitial cells in the CD39-null hearts compared to WT hearts. To quantify these findings immunoblot analysis for collagen and αSMA was performed. We found that collagen and αSMA were increased at Day 28 post-MI, in CD39-null hearts compared to WT hearts. Conclusion: CD39 ablation has detrimental effects on post-MI recovery, resulting in diminished cardiac performance and increased fibrosis.
A Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Final Analysis of Second Dose Expansion
Authors: Jesus G. Berdeja, Tara B. Gregory, Edward Faber, Jeffrey Matous, Lowell Hart, Joseph R. Mace, Edward R. Arrowsmith, Ian W. Flinn
Journal: Blood (2016)
Reactive Oxygen Species Localization Programs Inflammation to Clear Microbes of Different Size
Authors: Annika Warnatsch, Theodora-Dorita Tsourouktsoglou, Nora Branzk, Qian Wang, Susanna Reincke, Susanne Herbst, Maximiliano Gutierrez, Venizelos Papayannopoulos
Journal: Immunity (2017)

How the number of immune cells recruited to sites of infection is determined and adjusted to differences in the cellular stoichiometry between host and pathogen is unknown. Here, we have uncovered a role for reactive oxygen species (ROS) as sensors of microbe size. By sensing the differential localization of ROS generated in response to microbes of different size, neutrophils tuned their interleukin (IL)-1β expression via the selective oxidation of NF-κB, in order to implement distinct inflammatory programs. Small microbes triggered ROS intracellularly, suppressing IL-1β expression to limit neutrophil recruitment as each phagocyte eliminated numerous pathogens. In contrast, large microbes triggered ROS extracellularly, amplifying IL-1β expression to recruit numerous neutrophils forming cooperative clusters. Defects in ROS-mediated microbe size sensing resulted in large neutrophil infiltrates and clusters in response to small microbes that contribute to inflammatory disease. These findings highlight the impact of ROS localization on signal transduction.
REAL WORLD RELATIONSHIPS BETWEEN BASELINE Q WAVES, TIME FROM SYMPTOM ONSET AND CLINICAL OUTCOMES IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION PATIENTS: INSIGHT FROM THE VITAL HEART RESPONSE REGISTRY
Authors: Yinggan Zheng, Kevin Bainey, Ben Tyrrell, Neil Brass, Paul Armstrong, Robert Welsh
Journal: Journal of the American College of Cardiology (2017)
Single Asian Centre Experience in Acute Myeloid Leukaemia with Translocation 8;21 [t(8;21) (q22;q22)/RUNX1-RUNX1T1]
Authors: Sharifah Shahnaz Syed Abd Kadir, Lau Ngee Siang, Guan Yong Khee, Ong Tee Chuan, Tan Sen Mui, Subramanian Yegappan, Chang Kian Meng
Journal: Blood (2015)
A Novel BCR-ABL Mutation Predicts Resistance to Tyrosine Kinase Inhibitor (TKI) Therapy by a Unique Mechanism in Patients (pts) with Philadelphia-Positive (Ph+) Leukemia.
Authors: Alfonso Quintas-Cardama, Jorge Cortes, Hagop M. Kantarjian, Moshe Talpaz, Ji Wu, Feng Meng, Nicholas Donato
Journal: Blood (2006)
UNRAVELLING THE MECHANISMS OF MENTAL STRESS INDUCED MYOCARDIAL ISCHAEMIA: NOVEL INSIGHTS FROM INTRACORONARY MEASUREMENTS DURING CARDIAC CATHETERISATION
Authors: Satpal Arri, Rupert Williams, Kaleab Asrress, Matthew Lumley, Howard Ellis, Tiffany Patterson, Muhammed Khawaja, Divaka Perera, Brian Clapp, Michael Marber, Simon Redwood
Journal: Journal of the American College of Cardiology (2017)
Imaging peritoneal metastasis of gastric cancer with PET/CT and the radiotracer <sup>18</sup>F-fluorothymidine (<sup>18</sup>F-FLT):Proof-of-concept study.
Authors: Yoshitaka Honma, Takashi Terauchi, Ukihide Tateishi, Daisuke Kano, Kengo Nagashima, Natsuko T. Okita, Atsuo Takashima, Satoru Iwasa, Ken Kato, Tetsuya Hamaguchi, Yasuhiro Shimada, Narikazu Boku, Yasuhide Yamada
Journal: Journal of Clinical Oncology (2015)

11013 Background: Peritoneal metastasis (PM) is the most frequent form of metastasis in gastric cancer (GC), especially in diffuse type adenocarcinoma (DTAC). Microscopic PM can be identified accurately only in laparoscopic staging. The utility of metabolic imaging for GC is limited because DTAC are not 18F-fluorodeoxiglucose (FDG) avid, and the sensitivity of detecting PM by FDG/PET is known to be low in GC.18F-fluorothymidine (18F-FLT) was developed for imaging cellular proliferation, and its physiological accumulation to the intestinal tract is known to be less than FDG. In previous reports, 18F-FLT-PET had higher sensitivity than FDG and could visualize primary lesion or lymph node metastasis of GC with sufficient contrast, even in DTAC. In this proof-of-concept study, we explored the capability of 18F-FLT PET/CT for detecting macroscopic PM of GC. Methods: The key eligibility criteria were: (i) histologically proven gastric adenocarcinoma; (ii) PM detected by CT imaging; (iii) PS: 0-2; and (iv) sufficient organ function. 18F-FLT PET/CT was performed at the National Cancer Center Hospital, and the PET/CTs were interpreted by two independent radiologists who were not informed of the patient background. Detection sensitivity (DS) was defined as proportion of patients for whom 18F-FLT PET/CT noted at least one of the lesions detected in CT. Results: Twenty patients were enrolled in this study. One patient was diagnosed as gastric lymphoma by pathological review, who was excluded from the analysis. Fifteen of 19 patients (78.9%) had DTAC. PM was detected by 18F-FLT PET/CT in 14 of 19 patients (SUVmax: 1.697-13.21, DS = 73.7%). Classifying the patterns of PM into omental-cake-type (oPM) and nodule-type (nPM), seven of 19 patients (36.8%) had oPM, all of which were detected by 18F-FLT PET/CT (SUVmax: 1.771-13.21, DS = 100%). Meanwhile, in a total of 42 nodules detected by CT in the 12 patients with nPM, 20 nodules were detected by 18F-FLT PET/CT (SUVmax for positive cases: 1.697-6.524, DS = 47.6%). Conclusions: This proof-of-concept study clear the criteria of DS by 18F-FLT PET/CT for proceeding to the future study investigating clinical utility of 18F-FLT PET/CT for PM of GC. Clinical trial information: UMIN000009329.
CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL
Authors: Rebecca Gardner, Olivia Finney, Hannah Smithers, Kasey J Leger, Colleen E. Annesley, Corinne Summers, Christopher Brown, Stephanie Mgebroff, Catherine Lindgren, Karen Spratt, Assaf Oron, Daniel Li, Marie Bleakley, Julie R Park, Michael C Jensen
Journal: Blood (2016)
HYPERDENSE ARTERY SIGN ON COMPUTED TOMOGRAPHY IN ACUTE CORONARY SYNDROME
Authors: Yukio Mizuguchi, Hiroki Shibutani, Sho Hashimoto, Takeshi Yamada, Norimasa Taniguchi, Shunsuke Nakajima, Tetsuya Hata, Akihiko Takahashi
Journal: Journal of the American College of Cardiology (2017)
Survival Comparison of Patients With Cystic Fibrosis in Canada and the United States
Authors: Anne L. Stephenson, Jenna Sykes, Sanja Stanojevic, Bradley S. Quon, Bruce C. Marshall, Kristofer Petren, Josh Ostrenga, Aliza K. Fink, Alexander Elbert, Christopher H. Goss
Journal: Annals of Internal Medicine (2017)

In 2011, the median age of survival of patients with cystic fibrosis reported in the United States was 36.8 years, compared with 48.5 years in Canada. Direct comparison of survival estimates between national registries is challenging because of inherent differences in methodologies used, data processing techniques, and ascertainment bias.
Clinical response assessment after 2 cycles of neoadjuvant chemotherapy for primary breast cancer fails to predict for final clinical response, but does predict for pathological complete response
Authors: M. J. Beresford, Y. Chin, R. Burcombe, M. Ah-See, A. Makris
Journal: Journal of Clinical Oncology (2006)

667 Background: Neoadjuvant chemotherapy (NC) is increasingly being used for large primary breast carcinomas. Clinical trials have established its role in improving breast-conserving surgery (BCS) rates and have shown that complete pathological response (pCR) is associated with improved survival. Early evaluation of response is important for selecting patients with possible worse outcomes, who may benefit from alternative treatments. Methods: 107 women received NC for large operable breast cancers (T2–4, N1–2, M0). Patients received 6 cycles of FEC chemotherapy (5-FU 500mg/m 2 , epirubicin 75mg/m 2 , cyclophosphamide 500mg/m 2 every 21 days) prior to a planned operation. Clinical response was recorded at baseline, after 2 cycles of NC and on completion of 6 cycles. Baseline and completion ultrasound and/or mammography were performed and a pathological assessment of response was made in those patients who underwent surgery. Results: Median age was 50 (range= 29–78). Overall clinical response rate after 2 cycles of chemotherapy was 59.8% (64/107) and after 6 cycles was 84.1% (90/107). 56 patients (52.3%) underwent BCS, 37 (34.6%) mastectomy and 14 (13.1%) no operation. Overall pCR rate was 15.0% (16/107). Of the 43 patients who failed to respond clinically after 2 cycles, 27 (62.8%) went on to exhibit a clinical response on completion of chemotherapy. 3 (7.0%) patients went on to have a complete clinical response and 21 (48.8%) underwent BCS. However, none of these 43 patients demonstrated a pCR. Conclusions: Lack of clinical response after 2 cycles of neoadjuvant chemotherapy does not preclude clinical response after further treatment with the same schedule, and many women will have sufficient down-staging to enable breast-conserving surgery. However, a pathological complete response is unlikely if no clinical response is observed after 2 cycles. No significant financial relationships to disclose.
¿ES LA CALPROTECTINA FECAL UN INDICADOR ÚTIL PARA DETECTAR RECURRENCIA CON LA CÁPSULA ENDOSCÓPICA EN LOS PACIENTES CON ENFERMEDAD DE CROHN?
Authors: N Alonso Lázaro, M Iborra Colomino, C Satorres Paniagua, M Bustamante Balén, L Argüello Viúdez, M Ponce Romero, P Nos Mateu, V Pons Beltrán
Journal: Endoscopy (2015)

Introducción: La capsula endoscópica (CE) es una herramienta útil en la valoración de actividad en los pacientes con enfermedad de Crohn (EC). Se ha sugerido que la calprotectina fecal (CF) podría ser un marcador de actividad en la monitorización y detección de recurrencia en estos pacientes intervenidos. Sin embargo los estudios que relacionen ambas técnicas son escasos.
India should support Sania Nishtar for next director general of WHO
Authors: Mahesh Devnani
Journal: BMJ (2017)

The three equally strong finalists for the next director general of the World Health Organization are Tedros Adhanom Ghebreyesus of Ethiopia, Sania Nishtar of Pakistan, and David Nabarro of the UK.1

Whom should India support, and why?

Of the three finalists, Nishtar has both understanding of the health …
Traumatic Brain Injury–Related Emergency Department Visits, Hospitalizations, and Deaths — United States, 2007 and 2013
Authors: Christopher A. Taylor, Jeneita M. Bell, Matthew J. Breiding, Likang Xu
Journal: MMWR Surveillance Summaries (2017)

Traumatic brain injury (TBI) has short- and long-term adverse clinical outcomes, including death and disability. TBI can be caused by a number of principal mechanisms, including motor-vehicle crashes, falls, and assaults. This report describes the estimated incidence of TBI-related emergency department (ED) visits, hospitalizations, and deaths during 2013 and makes comparisons to similar estimates from 2007.
SOTALOL VERSUS OTHER ANTI-ARRHYTHMIC AGENTS FOR PREVENTION OF POST-OPERATIVE SUPRAVENTRICULAR ARRHYTHMIAS AFTER CARDIAC SURGERY: META-ANALYSIS OF RANDOMIZED CONTROLLED STUDIES
Authors: Arun Kanmanthareddy, Madhu Reddy, Dixitha Anugula, Venkata Alla, Claire Hunter, Aryan Mooss, Madhav Lavu, Sudharani Bommana, Donita Atkins, Andrea Natale, Dhanunjaya Lakkireddy
Journal: Journal of the American College of Cardiology (2017)
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Authors: Jeffrey I. Weitz, Anthonie W.A. Lensing, Martin H. Prins, Rupert Bauersachs, Jan Beyer-Westendorf, Henri Bounameaux, Timothy A. Brighton, Alexander T. Cohen, Bruce L. Davidson, Hervé Decousus, Maria C.S. Freitas, Gerlind Holberg, Ajay K. Kakkar, Lloyd Haskell, Bonno van Bellen, Akos F. Pap, Scott D. Berkowitz, Peter Verhamme, Philip S. Wells, Paolo Prandoni
Journal: New England Journal of Medicine (2017)

Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin.
White adipose tissue inflammation and breast cancer progression.
Authors: Neil M. Iyengar, Patrick G. Morris, Xi Kathy Zhou, Hanhan Wang, Ayca Gucalp, Dilip D. Giri, Michael D Harbus, Joseph Park, Samuel S Park, Monica Morrow, Clifford A. Hudis, Andrew Dannenberg
Journal: Journal of Clinical Oncology (2015)

11001 Background: Obesity is a poor prognostic factor for breast cancer (BC) survivors. White adipose tissue (WAT) inflammation (WATi) occurs in the breasts of most obese/overweight individuals, and also in some who are normal weight. We demonstrated that breast WATi is associated with several molecular changes including activation of NF-κB and elevated aromatase expression that could contribute to tumor progression. Additionally, WATi correlates with circulating changes including hyperinsulinemia that occur in the metabolic syndrome, a poor prognostic feature for BC. Here we examine the impact of breast WATi on BC progression. Methods: We conducted a case-control study nested within a cohort of 610 patients (pts) with invasive BC who underwent mastectomy from 2001 – 2006. Case pts were women who developed distant relapse while control subjects remained free of disease with follow up to 2014. Controls were matched (1:1) on age at diagnosis, BMI, receptor status, grade, T stage, N stage, use of adjuvant therapy, and co-morbidities. WATi, detected by CD68 immunostain, was defined by the presence of dead/dying adipocytes surrounded by macrophages known as crown-like structures of the breast (CLS-B). Distant recurrence free survival (dRFS) was compared by CLS-B status using Cox regression. Risk of distant relapse by CLS-B status was examined by conditional logistic regression analysis. Results: Adequate WAT was available for 250 subjects. Among pts who developed distant relapse (n = 127), median dRFS was worse for pts with breast WATi (20 months [mo], range 16-26) than those without WATi (26 mo, range 20-34; hazard ratio [HR] 1.44, 95% confidence interval [CI] 1.00-2.06, P < 0.05). The association between WATi and shorter dRFS remained significant in multivariable analysis (HR 1.83, 95% CI 1.07-3.13, P = 0.03). A higher proportion of pts who developed distant relapse had breast WATi at index mastectomy (52/127, 41%) than those who remained disease free (46/123, 37%), though not statistically significant as the study was underpowered for this endpoint (P = 0.76). Conclusions: In pts with recurrent BC, breast WATi is an adverse independent prognostic variable. These findings support further study of WATi as a targetable biomarker of BC progression.
ACQUISITION OF TIME-RESOLVED BRACHIAL PRESSURE WAVEFORMS FROM CUFF-BASED PULSE VOLUME RECORDINGS
Authors: Timothy S. Phan, Jumana Dakka, Amer Ahmed Syed, Izzah Vasim, Harry G. Oldland, Uzma Kewan, Scott R. Akers, Julio A. Chirinos
Journal: Journal of the American College of Cardiology (2017)
ISOLATED CARDIAC SARCOIDOSIS MIMICKING HYPERTROPHIC CARDIOMYOPATHY
Authors: Laura Ueberham, Ingo Paetsch, Cosima Jahnke, Ricardo Spampinato, Sebastian Hilbert, Kerstin Bode, Elena Efimova, Michael Doering, Daniela Husser, Karin Klingel, Gerhard Hindricks, Borislav Dinov
Journal: Journal of the American College of Cardiology (2017)
NOVEL PLANE OF MEASUREMENT TO EVALUATE ACCURATE VALVE SIZE IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Yash Jobanputra, Brandon Jones, Kimi Sato, Kinjal Banerjee, Krishna Kandregula, Amar Krishnaswamy, Stephanie Mick, Jose Navia, Samir Kapadia
Journal: Journal of the American College of Cardiology (2017)
VEGF165-induced vascular permeability requires NRP1 for ABL-mediated SRC family kinase activation
Authors: Alessandro Fantin, Anastasia Lampropoulou, Valentina Senatore, James T. Brash, Claudia Prahst, Clemens A. Lange, Sidath E. Liyanage, Claudio Raimondi, James W. Bainbridge, Hellmut G. Augustin, Christiana Ruhrberg
Journal: The Journal of Experimental Medicine (2017)

The vascular endothelial growth factor (VEGF) isoform VEGF165 stimulates vascular growth and hyperpermeability. Whereas blood vessel growth is essential to sustain organ health, chronic hyperpermeability causes damaging tissue edema. By combining in vivo and tissue culture models, we show here that VEGF165-induced vascular leakage requires both VEGFR2 and NRP1, including the VEGF164-binding site of NRP1 and the NRP1 cytoplasmic domain (NCD), but not the known NCD interactor GIPC1. In the VEGF165-bound receptor complex, the NCD promotes ABL kinase activation, which in turn is required to activate VEGFR2-recruited SRC family kinases (SFKs). These results elucidate the receptor complex and signaling hierarchy of downstream kinases that transduce the permeability response to VEGF165. In a mouse model with choroidal neovascularisation akin to age-related macular degeneration, NCD loss attenuated vessel leakage without affecting neovascularisation. These findings raise the possibility that targeting NRP1 or its NCD interactors may be a useful therapeutic strategy in neovascular disease to reduce VEGF165-induced edema without compromising vessel growth.
CHARACTERISTICS AND OUTCOMES OF PATIENTS DISCHARGED WITHOUT STATINS AFTER AN ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS FROM THE COMBINED FAST-MI 2005-2010 COHORTS
Authors: Francois Schiele, Jean Ferrières, Etienne Puymirat, Nicolas Meneveau, Tabassome Simon, Nicolas Danchin
Journal: Journal of the American College of Cardiology (2017)
Changes in Serum B-Cell Maturation Antigen Levels Are a More Rapid Indicator of Therapeutic Response or Disease Progression for Patients with Multiple Myeloma
Authors: Kyle Udd, Haiming Chen, Mingjie Li, Camilia M Soof, Christian Casas, Soudabeh Etessami, Zachary Gross, Matthew Ghermezi, James Wang, Eric Sanchez, Cathy S Wang, Marsiye Emamy-Sadr, Regina Swift, James R. Berenson
Journal: Blood (2016)
Assessment of Peripheral Blood (PB) Blast Decrease Rate by Multiparameter Flow Cytometry: A New Prognostic Factor in Acute Myeloblastic Leukaemia (AML). A Goelams Study.
Authors: Francis Lacombe, Christine Arnoulet, Marc Maynadie, Arnaud Pigneux, Norbert Vey, Olivier Casasnovas, Francis Witz, Marie C. Bene
Journal: Blood (2006)
A TICAGRELOR LOADING RESULTS IN INCREASED PLASMA S-NITROSOTHIOLS FORMATION ACUTELY IN PATIENTS WITH STABLE ANGINA UNDERGOING PCI BUT NOT ON CHRONIC THERAPY: POSSIBLE EVIDENCE OF AN ACUTE PLEIOTROPIC EFFECT
Authors: Fairoz Belary Abdul, Richard Anderson, Laurence Thornhill, Keith Morris, Phillip E. James
Journal: Journal of the American College of Cardiology (2017)
THE IMPACT OF RIGOROUS QUALITY IMPROVEMENT ON 3D ECHOCARDIOGRAPHY IMAGE AND DATA QUALITY IN AN INTERNATIONAL MULTISITE RANDOMIZED TRIAL
Authors: Anna Lisa Crowley, Eric Yow, Dawn Rabineau, Huiman Barnhart, Jennifer White, Eric Velazquez, Melissa Daubert, Mitchell Krucoff, Sunil Rao, Pamela S. Douglas
Journal: Journal of the American College of Cardiology (2017)